1/2- Bangladesh Center for Global Environmental and Occupational Health- Bangladesh (GEOHealth-II)

Long Term Effects of Household Air Pollution (HAP) Reduction on Cardio-pulmonary and Immune Function Outcomes - a Household Level Randomized mHealth Intervention Trial

Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass (wood, agricultural residue, cow dung, etc.) fuel use for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use, especially in low- and middle-income countries (LMICs). Earlier the investigators showed that Liquid Petroleum Gas (LPG) for 24 months, reduced personal PM2.5 exposure by 58.17 percent which induced novel changes in immune and inflammatory responses in the participants; however cardiopulmonary markers remained relatively stable in post-intervention assessment.

In this study, the investigators aim to evaluate the effects of mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention on adoption and exclusive use of LPG. The investigators also aimed to observe whether long-term effects of HAP reduction can impact the subclinical measures of cardio-vascular and pulmonary dysfunction and regulate innate and inflammatory immune function among women and children in semi-rural settings in Bangladesh. The investigators will also investigate the influence of exposure to HAP on antibody response to vaccines (adaptive immunity). The BCC intervention will be provided by conducting a large household level randomized controlled trial by educational intervention using mHealth based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine.

Study Overview

Detailed Description

Background:

Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass fuel (wood, agricultural residue, cow dung, etc.) used for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use such as Liquid Petroleum Gas, especially in low- and middle-income countries (LMICs).

Rationale: In the earlier GEOHealth (Round-I) study, the investigators have shown that LPG for 24 months, reduced personal PM2.5 exposure by 58.2 percent which induced novel changes in innate immune and inflammatory responses in women but the changes in chronic cardio-pulmonary markers were not prominent, most likely due to short duration of follow up and probably impact of ambient pollution. Moreover, sustained use of LPG could be challenging as earlier GEOHealth (Round-I) study provided the cook stove and supply of LPG free of cost. A post-completion screening showed >70% households continued using LPG albeit not exclusively. It is plausible that an intervention using mobile phone-based application can improve the exclusive use of LPG in the communities.

Hypothesis:

  1. The mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention can be easily incorporated in Government policy that can promote adoption, and increase exclusive use of LPG in the communities.

    The long-term effect of HAP reduction can be associated with-

  2. subclinical measures of cardio-vascular and pulmonary dysfunction.
  3. balanced changes in innate/ inflammatory and adaptive immune function (vaccine response).

Objectives: To evaluate

  1. The effects of a scalable educational intervention (using mHealth application) on adoption and exclusive use of LPG.
  2. The long-term effects of HAP reduction on subclinical measures of cardio-vascular and pulmonary dysfunction.
  3. The long-term effects of HAP reduction on innate/ inflammatory immune function among women and children and to investigate the influence of HAP exposure on antibody response to vaccines (adaptive immunity).

Methods: The investigators will conduct a large household level randomized controlled trial by educational intervention using mobile phone (mHealth) based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area-wise (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine.

Outcome measures/variables: Personal and surrounding area PM2.5 and BC level will be measured at pre- and post-intervention. Lung function and lung pathology will be assessed through spirometry, Chest X-ray, and High-resolution Computed tomography of the chest (HRCT). Preclinical makers of cardiovascular diseases (CVD) will include blood pressure and EKG. Markers of metabolic dysfunction will be assesses by measuring HbA1c and fasting lipid profile. Immune function will be assessed by phenotyping of Immune cells, functional cytotoxic killer cells, oxidative stress of lymphocytes.

Study Type

Interventional

Enrollment (Estimated)

1000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Mohammad Yunus, MBBS, M.Sc.
  • Phone Number: 2210 +8802222277001-10
  • Email: myunus@icddrb.org

Study Locations

      • Dhaka, Bangladesh, 1212
        • Recruiting
        • International Centre for Diarrhoeal Diseases Research, Bangladesh
        • Contact:
        • Principal Investigator:
          • Rubhana Raqib, PhD
        • Sub-Investigator:
          • Mohammad Yunus, M.Sc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants in the previous GEOHEALTH round-I study
  • Aged between 25 and 70 years
  • Live in biomass-using home with traditional stoves
  • Non-smoker and live with non-smokers
  • Exposed to <10 µg/L of water arsenic

Exclusion Criteria:

  • Known to have immune related illness or taking any prescription medication (particularly those that suppress or enhance immune function)
  • Known to have any clinical events of CVD or lung disease, including stroke or coronary heart disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: mHealth arm
mHealth arm will receive mobile phone based behavior change communication intervention to exclusively use clean fuel LPG for domestic cooking.
We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
Other Names:
  • value sensitive design (VSD), Fogg Behavior Model (FBM), System Usability Scale (SUS)
No Intervention: Control arm
Control arm will receive no mHealth based intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Personal air pollution
Time Frame: Pre-intervention
Measurement of personal air pollution (PM2.5 and BC level) by personal air pollution monitoring device
Pre-intervention
Personal air pollution
Time Frame: Two-year post intervention
Measurement of personal air pollution (PM2.5 and BC level) by personal air pollution monitoring device
Two-year post intervention
Ambient air pollution
Time Frame: Pre-intervention
Measurement of ambient air pollution (PM2.5) by ambient air monitoring device
Pre-intervention
Ambient air pollution
Time Frame: Two-year post intervention
Measurement of ambient air pollution (PM2.5) by ambient air monitoring device
Two-year post intervention
Lung function assessment by spirometry
Time Frame: Pre-intervention
Lung function assessment by spirometry
Pre-intervention
Lung function assessment by spirometry
Time Frame: Two-year post intervention
Lung function assessment by spirometry
Two-year post intervention
Assessment lung pathology by chest X-ray and High-resolution Computed tomography
Time Frame: Pre-intervention
Lung pathology will be assessed by chest X-ray for all participants and high-resolution Computed tomography of the chest (HRCT) will be performed in selected participants.
Pre-intervention
Assessment lung pathology by chest X-ray and High-resolution Computed tomography
Time Frame: Two-year post intervention
Lung pathology will be assessed by chest X-ray for all participants and high-resolution Computed tomography of the chest (HRCT) will be performed in selected participants.
Two-year post intervention
Measurement of cardiovascular disease (CVD) markers by measuring blood pressure
Time Frame: Pre-intervention
Preclinical markers of CVD assessment by blood pressure
Pre-intervention
Measurement of cardiovascular disease (CVD) markers by measuring blood pressure
Time Frame: Two-year post intervention
Preclinical markers of CVD assessment by blood pressure
Two-year post intervention
Measurement of cardiovascular disease (CVD) markers by performing EKG
Time Frame: Pre-intervention
Preclinical markers of CVD assessment by EKG
Pre-intervention
Measurement of cardiovascular disease (CVD) markers by performing EKG
Time Frame: Two-year post intervention
Preclinical markers of CVD assessment by EKG
Two-year post intervention
Evaluation of metabolic markers (diabetes) in blood at baseline.
Time Frame: Pre-intervention
Assessment of metabolic dysfunction by measuring HbA1c
Pre-intervention
Evaluation of metabolic markers (diabetes) in blood after intervention.
Time Frame: Two-year post intervention
Assessment of metabolic dysfunction by measuring HbA1c
Two-year post intervention
Evaluation of metabolic markers (CVD) in blood.
Time Frame: Pre-intervention
Assessment of metabolic dysfunction by measuring fasting lipid profile.
Pre-intervention
Evaluation of metabolic markers (CVD) in blood.
Time Frame: Two-year post intervention
Assessment of metabolic dysfunction by measuring fasting lipid profile.
Two-year post intervention
Assessment of immune function in blood cells
Time Frame: Pre-intervention
Immune function will be assessed by phenotyping using flowcytometry
Pre-intervention
Assessment of immune function in blood cells
Time Frame: Two-year post intervention
Immune function will be assessed by phenotyping using flowcytometry
Two-year post intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health hazards of industrial waste - a pilot study
Time Frame: In one year
Health hazards of industrial waste reflected by measurement of polycyclic aromatic hydrocarbons, polychlorinated dibenzodioxins and dibenzofurans in adjacent water bodies
In one year
Occupational health hazard among garments/textile factory workers - a pilot study
Time Frame: In one year
Prevalence of lung function abnormalities among garments/textile mills/power loom factory workers through structured questionnaire based data collection and spirometry.
In one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2023

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

August 29, 2022

First Submitted That Met QC Criteria

October 4, 2022

First Posted (Actual)

October 6, 2022

Study Record Updates

Last Update Posted (Actual)

March 22, 2024

Last Update Submitted That Met QC Criteria

March 20, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All data collected of the proposed study will be made fully available to any bonafide researcher. In general, the investigators will follow the data sharing plan developed and practiced by the NIH-funded grantees. Any data request by external researchers will be reviewed by the PIs and the AOC and the requested specific data will be made available to the through a secured web-based interface developed specifically for this project. In general, data will be made available six months after the manuscript reporting results from those specific sets of data are accepted for publication and all data requests will be processed within six months from the receipt of the request in writing. Any data requests with potential conflicts will be reviewed and decided by the AOC.

IPD Sharing Time Frame

Data will be available 6 months after manuscripts accepted for publication

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Air Pollution

Clinical Trials on mHealth based behavioral change communication intervention

3
Subscribe